DiaTech reports MiCK data

DiaTech Oncology (Brentwood, Tenn.) reported data from a study of its Microculture Kinetic (MiCK) assay to predict patient response to chemotherapy in ovarian cancer. Patients who received the best chemotherapy as predicted by the MiCK assay had significantly improved overall survival and overall response rates (ORR) vs. patients who received chemotherapy not recommended by the assay at 24 months (92% and 82%, respectively, vs. 76% and 54%, p=0.01 and p=0.04). The prospective, non-randomized, investigator-blinded study enrolled 128 patients. Data will be presented at the American Society of Clinical Oncology meeting in Chicago in June. ...